Evidence map›Paper›PMID 41983039›Full record

ArticleFrontiers in bioinformatics2026

molIEreVIS: exploring and interpreting the evidence behind drug repurposing predictions.

Amal Alnouri, Andreas Hinterreiter, Christian Steinparz, Labinot Bajraktari, Sebastian Burgstaller-Muehlbacher, Markus Bauer, Gregorio Alanis-Lobato, Marc Streit

Abstract read
In one paragraph

Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amal AlnouriVisual Data Science Lab, Johannes Kepler University, Linz, Austria.
Andreas HinterreiterVisual Data Science Lab, Johannes Kepler University, Linz, Austria.
Christian SteinparzVisual Data Science Lab, Johannes Kepler University, Linz, Austria.
Labinot BajraktariBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Sebastian Burgstaller-MuehlbacherBoehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Markus BauerBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Gregorio Alanis-LobatoBoehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Marc StreitVisual Data Science Lab, Johannes Kepler University, Linz, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Finding new uses for existing drugs, known as drug repurposing, is a widely adopted drug development strategy in the pharmaceutical industry. Computational drug repurposing leverages vast biomedical data to prioritize repurposing candidates. Once these candidates are prioritized, domain experts face the burden of evaluating their true potential. Methods: In this work, we propose a visualization-based approach to address this challenge for a multimodal class of computational drug repurposing, where heterogeneous evidence modalities are integrated. We conducted a design study in close collaboration with domain experts, from which we derived a domain abstraction of the expert assessment process. Grounded in this abstraction, we developed an interactive visualization approach that explicitly models the expert reasoning process. We applied the proposed approach to create a prototype implementation, molIEreVIS, in the context of an operational drug repurposing pipeline. We used this prototype to collect qualitative feedback from domain experts actively engaged in assessing computational drug repurposing candidates. Results: The results demonstrate the potential of our approach to support insights and reasoning in this process and reveal directions for enhancements and future work.

Indexed as

drug repurposingindication expansioninterpretabilityknowledge graphvisualization

Identifiers

PMID41983039
PMCPMC13071390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.